New drug combo tested for tough cancers
NCT ID NCT06537310
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This early-phase study tests an experimental drug (RO7567132) alone or with another drug (atezolizumab) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 34 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
BC Cancer ? Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Clinica Universidad de Navarra Madrid
Madrid, 28027, Spain
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Kinghorn Cancer Centre
Darlinghurst, New South Wales, 2010, Australia
-
McGill University Health Center
Montreal, Quebec, H4A 3J1, Canada
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Rigshospitalet
København Ø, 2100, Denmark
-
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.